# Ifosfamide: bladder protection with mesna and fluids, and ifosfamide encephalopathy

Source: https://onco.cc/protocols/ifosfamide-bladder-protection-and-encephalopathy/  
OnCo record `ifosfamide-bladder-protection-and-encephalopathy` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ifosfamide can irritate the bladder and make it bleed, and it can affect the brain, causing confusion or unusual sleepiness. To protect the bladder you are given a drug called mesna and plenty of fluid, and your urine is tested. Tell your team straight away about blood in your urine, stinging when you pee, confusion or drowsiness. Your own team's protocol comes first.

## Summary

Bladder. Both labels require mesna and fluids with ifosfamide and differ in detail. The US label (Ifex, revised October 2026) asks for at least 2 litres of oral or intravenous fluid a day, a urinalysis before each dose, and ifosfamide withheld until complete resolution if there are more than 10 red cells per high power field; it reports haematuria in 44% without mesna and 21% with it, and visible haematuria in 11% and 5%. The UK SmPC (Baxter, November 2024) sets no red cell threshold: it asks for laboratory urine analysis before and at the end of each course, checks for blood and protein at regular intervals (4-hourly if possible), at least 2 litres of fluid in 24 hours on the intermittent regimen, and lists cystitis and impaired renal function as contraindications. Mesna is dosed as a percentage of the ifosfamide dose by weight. US label (Mesnex): 20% intravenously at 0, 4 and 8 hours (60% in total), or 20% intravenously at 0 hours then 40% by mouth at 2 and 6 hours (100% in total), a ratio not established for ifosfamide above 2 g/m2 a day. UK SmPC: the same standard schedule, 40% at 0, 3, 6 and 9 hours (160%) for children and for people whose urothelium may already be damaged or who are not protected by the standard dose, and with a 24-hour ifosfamide infusion a 20% bolus, 100% with the infusion and 60% over the next 12 hours (180%). The US and UK mesna texts both say mesna does not prevent haemorrhagic cystitis in all patients.

Brain. The US label reports central nervous system toxicity in 15% (154 of 1,001) and names as risk factors high dose, hypoalbuminaemia, impaired renal function, poor performance status, bulky abdominal or pelvic disease, nephrotoxic treatment including cisplatin, CNS-active drugs and alcohol. A 2020 review of seven studies found performance status 2 to 4, several risk factors together, renal insufficiency and hypoalbuminaemia appear to be risk factors, and insufficient evidence for most of the others. Both labels say to monitor for encephalopathy and to discontinue ifosfamide if it develops (the UK SmPC and the US boxed warning; section 5.2 of the US label says dose interruption or permanent discontinuation may be required); the UK SmPC says most cases resolve within 48 to 72 hours of stopping. On methylene blue the wording is weak in both: "Consider" for treatment (US), "may be considered" for treatment and prophylaxis (UK). The evidence is case reports and retrospective series with no prospective randomised trial; a 2025 narrative review says management is essentially discontinuation and hydration and that no drug has been proven to be effective, while saying methylene blue and thiamine can still be used, as they are in more serious cases. Neither label mentions thiamine. This is not ICANS, which follows CAR T cells and T-cell engagers and has its own protocol. Each unit's own ifosfamide protocol comes first.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: ifosfamide haemorrhagic cystitis; ifosfamide hemorrhagic cystitis; mesna with ifosfamide; mesna dosing; ifosfamide encephalopathy; ifosfamide-induced encephalopathy; ifosfamide neurotoxicity; ifosfamide confusion; methylene blue for ifosfamide encephalopathy; blood in urine on ifosfamide

## Connected records

- drugs: [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Ifosfamide](https://onco.cc/drugs/ifosfamide/), [Mesna](https://onco.cc/drugs/mesna/)
- protocols: [Acute oncology telephone triage: the 24-hour helpline and the UKONS red, amber and green grading](https://onco.cc/protocols/acute-oncology-telephone-triage/), [Bladder symptoms and BCG infection after intravesical therapy for non-muscle-invasive bladder cancer](https://onco.cc/protocols/bladder-symptoms-and-infection-after-intravesical-therapy/), [ICANS after CAR T-cell therapy: ICE score, ASTCT grading, steroids and seizure management](https://onco.cc/protocols/icans-grading-and-management/), [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/), [Renal dose adjustment of anticancer drugs in reduced kidney function](https://onco.cc/protocols/renal-dose-adjustment-of-anticancer-drugs/), [Stem cell transplant: conditioning, the low blood count phase and engraftment monitoring](https://onco.cc/protocols/hct-conditioning-and-engraftment-care/)
- terms: [Alkylating agents and antimetabolites](https://onco.cc/terms/alkylating-agent/)

---
JSON: https://onco.cc/api/v1/entities/ifosfamide-bladder-protection-and-encephalopathy.json